World News: 13:30 GMT Friday 9th December 2016 . [ Novartis International AG via Thomson Reuters ONE via SPi World News ] MONALEESA-2 analyses demonstrate superior PFS with LEE011 plus letrozole in pre-defined patient subgroups - from de novo ... SPi World News, 1 month ago
More from: WVB, PM 360...and 3 other sources
Novartis announces Zykadia® first-line study results showing 16.6 month progression-free survival in patients with ALK+ advanced NSCLC
- Patients without brain metastases at diagnosis experienced median progression-free survival of 26.3 months, the longest seen in a global Phase III study in ALK+ NSCLC(1)- Patients with measurable brain metastases in the Zykadia arm experienced an ...TickerTech.com, 1 month ago Novartis data shows Treatment-free Remission rates are consistently above 50% regardless of reason for switch to Tasigna® from Gleevec® Yahoo! Finance, 1 month ago Novartis presents results from first global registration trial of CTL019 in pediatric and young adult patients with r/r B-ALL Bio-Medicine, 1 month ago
The mad-scramble within President Robert Mugabe's warring Zanu PF to control the frail and mysterious leader of a secretive religious sect, Madzibaba Wimbo, is intensifying — with the 94-year-old now living under 24-hour guard by soldiers armed to ...Zimbabwe Daily, 1 month ago Zanu-PF factions fight for Mugabe's mysterious prophet Bulawayo24 News, 1 month ago Soldiers 'cut off' Mugabe prophet Daily News Zimbabwe, 1 month ago
Novartis data at ASH and SABCS showcase latest innovations in development for patients with blood disorders and breast cancer
EAST HANOVER, N.J., Nov. 16, 2016 /PRNewswire/ -- Novartis will present data demonstrating the latest advancements from its oncology research program at the 58 th American Society of Hematology (ASH) Annual Meeting & Exposition, San Diego, December ...Yahoo! Singapore, 2 months ago
on your WebpageAdd Widget >Get your members hooked!